

# Utilising an app-based behavioural intervention to increase the light exposure of office workers: A pilot randomised controlled trial

<b>Submission date</b> 12/07/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/07/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 07/12/2022	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This study aims to test a behavioural intervention designed to increase the daytime light exposure of office workers. As this is a pilot trial, the researchers are primarily interested in how feasible and acceptable the study design/procedures and intervention are.

### Who can participate?

Healthy office workers who are working and living within the Oxford Ring Road, full-time, in August/September/October/November/December of this year (2021), are aged 25-45 years, are an Android/iOS smartphone user (with a consistent internet connection indoors and outdoors) and are able to read and understand English.

### What does this study involve?

Participants will be sent an envelope containing an actigraph device and instructions about the study, including how to download the study app. This envelope will be sent to their home address. Participants will need to download the OxTrack app from the Google Play Store or Apple App Store. For the duration of the study (4 weeks), participants will need to wear the actigraph device on their non-dominant wrist. Participants will also need to complete daily surveys in the OxTrack app for the duration of the 4 weeks: 'My Sleep' (when they get out of bed), 'My Day' (just before bed) and 'My Mood' (between 8pm and 9pm). Furthermore, participants will be asked to complete three other surveys at the start of week 1, end of week 2 and the end of week 4. At the end of week 4, participants will be asked to complete one additional survey. At the end of week 2 participants will also be asked to read a poster. For weeks 3 and 4 participants will be asked to keep an eye out for "click me" notifications. Participants will complete the study whilst continuing their normal day-to-day activities. Once the study is complete, participants will be asked to return the actigraph device in a pre-paid envelope.

What are the possible benefits and risks of participating?

Participants will be paid £100 for their participation. The questionnaires and data collected by the sensors are minimally intrusive. Throughout the study participants will be asked to report on their emotional state, which could cause distress.

Where is the study run from?

University of Oxford (UK)

When is the study starting and how long is it expected to run for?

February 2021 to December 2021

Who is funding the study?

1. SLL (UK)
2. Department of Experimental Psychology, University of Oxford (UK)
3. St Catherine's College, University of Oxford (UK)
4. University of Oxford Medical Sciences Internal Fund (UK)
5. Wellcome Trust (UK)

Who is the main contact?

Dr Manuel Spitschan  
manuel.spitschan@tum.de

## Contact information

### Type(s)

Scientific

### Contact name

Dr Manuel Spitschan

### ORCID ID

<https://orcid.org/0000-0002-8572-9268>

### Contact details

Department of Sport and Health Sciences  
Technical University of Munich  
Georg-Brauchle-Ring 60/62  
München  
Germany  
D-80992  
+49 (0)89 289 – 24544  
manuel.spitschan@tum.de

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

MS IDREC R75745

# Study information

## Scientific Title

Utilising an app-based 'nudge' behavioural intervention to increase the light exposure of office workers: A double-blind, parallel group, matched-pairs, randomised placebo-controlled superiority pilot trial

## Acronym

OxTrack

## Study objectives

Current study hypothesis as of 08/03/2022:

The primary objectives for this study focus on assessing the feasibility and acceptability of the intervention and trial procedures.

### Feasibility:

1. To assess the mean percentage of nudge notifications read by participants
2. To assess the percentage of participants that pass the Light Quiz
3. To assess how many prospective participants complete the screening survey
4. To assess what percentage of prospective participants are eligible to participate in the study
5. To assess what percentage of eligible prospective participants consent to data collection after screening
6. To assess what percentage of eligible participants are successfully matched in a pair
7. To assess what percentage of participants drop out/are lost to follow up
8. To qualitatively assess why participants did not consent to data collection/why they dropped out of the study
9. To assess the percentage of participants who were blind to their group allocation
10. To assess whether the blinding of researchers in the study was successful
11. To assess the percentage of contamination in the study
12. To assess what percentage of participants engaged in co-intervention
13. To assess the mean percentage of daily questionnaires completed with valid data
14. To assess the mean percentage of repeat questionnaires completed with valid data
15. To assess the average percentage of actigraphs worn with valid data

### Acceptability:

1. To assess the acceptability of the nudge intervention using the Theoretical Framework of Acceptability (TFA)
2. To assess the acceptability of the placebo nudge using the TFA
3. To assess the acceptability of the study procedures using the TFA
4. To qualitatively assess the barriers and facilitators participants experienced when attempting to/carrying out the behaviours.
5. To assess what percentage of participants provide valid secondary outcome data

### Sample size calculation:

1. To carry out a sample size calculation for a future definitive main trial

### Previous study hypothesis:

The primary objectives for this study focus on assessing the feasibility and acceptability of the intervention and trial procedures.

### Feasibility:

1. To assess the average percentage of nudge notifications read by participants
2. To assess the percentage of participants that pass a domain-specific quiz
3. To assess how many prospective participants complete the screening survey
4. To assess what percentage of prospective participants are eligible to participate in the study
5. To assess what percentage of eligible prospective participants consent to data collection after screening
6. To assess what percentage of eligible participants are successfully matched in a pair
7. To assess what percentage of participants drop out/are lost to follow up
8. To qualitatively assess why participants did not consent to data collection/why they dropped out of the study
9. To assess the percentage of participants who were blind to their group allocation
10. To assess whether the blinding of researchers in the study was successful
11. To assess the percentage of contamination in the study
12. To assess what percentage of participants engaged in co-intervention
13. To assess the average percentage of daily questionnaires completed with valid data
14. To assess the average percentage of repeat questionnaires completed with valid data
15. To assess the average percentage of actigraphs worn with valid data

### Acceptability:

1. To assess the acceptability of the nudge intervention using the Theoretical Framework of Acceptability (TFA)
2. To assess the acceptability of the placebo nudge using the TFA
3. To assess the acceptability of the study procedures using the TFA
4. To qualitatively assess the barriers and facilitators participants experienced when attempting to/carrying out the behaviours.
5. To assess what percentage of participants provide valid secondary outcome data

### Sample size calculation:

1. To carry out a sample size calculation for a future definitive main trial

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Current ethics approval as of 07/10/2021:

Approved 06/05/2021, first amendment approved 19/07/2021, second amendment approved 20/08/2021, third amendment approved 14/09/2021, University of Oxford Medical Sciences Interdivisional Research Ethics Committee (Research Services, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK; +44 (0)1865 616577; ethics@medsci.ox.ac.uk), ref: R75745/R001, first amendment ref: R75745/R002, second amendment ref: R75745/R003, third amendment ref: R75745/R004

### Previous ethics approval:

Approved 06/05/2021, University of Oxford Medical Sciences Interdivisional Research Ethics

Committee (Research Services, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK; +44 (0)1865 616577; ethics@medsci.ox.ac.uk), ref: R75745/R001; amendment approved 19/07/2021 (R75745/R002)

## **Study design**

Single-centre interventional double-blind parallel-group matched-pairs randomized placebo-controlled superiority pilot trial

## **Primary study design**

Interventional

## **Study type(s)**

Quality of life

## **Health condition(s) or problem(s) studied**

Improving the light exposure of office workers

## **Interventions**

Current intervention as of 08/03/2022:

Randomisation/allocation: sequence generation

The researchers will perform the assignment of individuals to treatment groups and the allocation of groups to intervention and placebo independently. First, using an optimal non-bipartite matching and matched randomization algorithm (Lu, Greevy, Xu, & Beck, 2012) (Greevy, et al., 2012) the researchers will create matched pairs based on age, gender and PSQI score. Second, using a true random number generator (sampling atmospheric noise), they will then assign group 1 and 2 arising from the matching to be either intervention or placebo on a 1:1 basis. Sequences will be generated randomly by using a computerised coin flip. The algorithm will choose the order of participants and the researchers will truncate after n places.

Allocation: concealment

Researcher 2 will recruit participants and score their online screening questionnaires.

Researcher 2 will be the only individual with access to the screening data. The ID, age, gender, and PSQI score of prospective participants who screen into the study and have agreed to take part in data collection, will be passed onto Researcher 1. Researcher 1 will act as the equivalent of a central randomised service, matching participants into pairs and randomly allocating individuals within those pairs to either the intervention or placebo group. Researcher 1 will have no contact with the participants and will not be involved with recruitment, screening, or data collection. Allocation concealment will be achieved as Researcher 2 who will be enrolling participants will not be able to anticipate which groups participants will be allocated to. Participants will be unaware of the allocation sequence.

Educational poster

For the nudges to act as reminders, participants will first have to be educated on how they can increase their daytime light exposure and why it is important for their health to do so. To this effect, the researchers have designed an educational poster that will be given to both groups (placebo and intervention) via a link sent by email on the last day of week 2. Participants will be asked not to save or download the poster.

Intervention

The researchers have designed 14 reminder nudges that will be delivered via the OxTrack app notifications to remind participants of the light exposure behaviours detailed in the educational

poster. One nudge will be delivered to each individual in the experimental group, daily at 9 am BST from the start of week 3 to the end of week 4 (14 reminder nudges for 14 days). Participants will receive the notifications whilst going about their daily lives.

#### Placebo

The placebo will superficially take on the appearance of the active reminder nudges. There are 14 placebo reminder nudges, one for each day of the intervention period. The placebo reminder nudges will be sent via OxTrack notifications at 9 am BST.

Previous intervention as of 07/10/2021:

Randomisation/allocation: sequence generation

The researchers will perform the assignment of individuals to treatment groups and the allocation of groups to intervention and placebo independently. First, using an optimal non-bipartite matching and matched randomization algorithm (Lu, Greevy, Xu, & Beck, 2012) (Greevy, et al., 2012) the researchers will create matched pairs based on age, gender and PSQI score. Second, using a true random number generator (sampling atmospheric noise), they will then assign group 1 and 2 arising from the matching to be either intervention or placebo on a 1:1 basis. Sequences will be generated randomly by using a computerised coin flip. The algorithm will choose the order of participants and the researchers will truncate after n places.

Allocation: concealment

Researcher 2 will recruit participants and score their online screening questionnaires. Researcher 2 will be the only individual with access to the screening data. The ID, age, gender, and PSQI score of prospective participants who screen into the study and have agreed to take part in data collection, will be passed onto Researcher 1. Researcher 1 will act as the equivalent of a central randomised service, matching participants into pairs and randomly allocating individuals within those pairs to either the intervention or placebo group. Researcher 1 will have no contact with the participants and will not be involved with recruitment, screening, or data collection. Allocation concealment will be achieved as Researcher 2 who will be enrolling participants will not be able to anticipate which groups participants will be allocated to. Participants will be unaware of the allocation sequence.

Educational poster

For the nudges to act as reminders, participants will first have to be educated on a domain-specific set of behaviours and why it is important for their health to do so. To this effect, the researchers have designed an educational poster that will be given to both groups (placebo and intervention) via a link sent by email on the last day of week 2. Participants will be asked not to save or download the poster.

Intervention

The researchers have designed 14 reminder nudges that will be delivered via the OxTrack app notifications to remind participants of the behaviours detailed in the educational poster. One nudge will be delivered to each individual in the experimental group, daily at 9 am BST from the start of week 3 to the end of week 4 (14 reminder nudges for 14 days). Participants will receive the notifications whilst going about their daily lives.

Placebo

The placebo will superficially take on the appearance of the active reminder nudges. There are 14 placebo reminder nudges, one for each day of the intervention period. The placebo reminder nudges will be sent via OxTrack notifications at 9 am BST.

Previous interventions:

Randomisation/allocation: sequence generation

The researchers will perform the assignment of individuals to treatment groups and the allocation of groups to intervention and placebo independently. First, using an optimal non-bipartite matching and matched randomization algorithm (Lu, Greevy, Xu, & Beck, 2012) (Greevy, et al., 2012) the researchers will create matched pairs based on age and gender. Second, using a true random number generator (sampling atmospheric noise), they will then assign group 1 and 2 arising from the matching to be either intervention or placebo on a 1:1 basis. Sequences will be generated randomly by using a computerised coin flip. The algorithm will choose the order of participants and the researchers will truncate after n places.

Allocation: concealment

Researcher 2 will recruit participants and score their online screening questionnaires.

Researcher 2 will be the only individual with access to the screening data. The age, gender and name of prospective participants who screen into the study and have agreed to take part in data collection will be passed onto Researcher 1. Researcher 1 will act as the equivalent of a central randomised service, matching participants into pairs and randomly allocating individuals within those pairs to either the intervention or placebo group. Researcher 1 will have no contact with the participants and will not be involved with recruitment, screening, or data collection.

Allocation concealment will be achieved as Researcher 2 who will be enrolling participants will not be able to anticipate which groups participants will be allocated to. Participants will be unaware of the allocation sequence.

Educational poster

For the nudges to act as reminders, participants will first have to be educated on a domain-specific set of behaviours and why it is important for their health to do so. To this effect, the researchers have designed an educational poster that will be given to both groups (placebo and intervention) via a link sent by email on the last day of week 2. Participants will be asked not to save or download the poster.

Intervention

The researchers have designed 14 reminder nudges that will be delivered via the OxTrack app notifications to remind participants of the behaviours detailed in the educational poster. One nudge will be delivered to each individual in the experimental group, daily at 8 am BST from the start of week 3 to the end of week 4 (14 reminder nudges for 14 days). Participants will receive the notifications whilst going about their daily lives.

Placebo

The placebo will superficially take on the appearance of the active reminder nudges. There are 14 placebo reminder nudges, one for each day of the intervention period. The placebo reminder nudges will be sent via OxTrack notifications at 8 am BST.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Feasibility:

1. Feasibility of the intervention will be measured using an app and quiz and the feasibility section of the custom feasibility and acceptability questionnaire at the end of the trial
2. Feasibility of the design and procedures will be measured using a screening survey, custom allocation/randomisation script consent forms, a follow-up questionnaire, the feasibility section

of the custom feasibility and acceptability questionnaire and a self-report question at the end of the trial

3. Feasibility of the design and procedures in terms of completeness will be assessed by calculating the average percentage of daily questionnaires completed with valid data (GoodBarber), the average percentage of repeat questionnaires completed with valid data (REDCap), and the average percentage of actigraphs worn with valid data at the end of the trial (added 20/07/2021)

Acceptability:

1. Acceptability of the intervention will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial
2. Acceptability of the placebo will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial
3. Acceptability of the study procedures will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial

Sample size calculation:

1. Sample size for a definitive main trial calculated using a non-central t-distribution (NCT) approach at the end of the trial

### **Key secondary outcome(s)**

Three secondary outcome domain-specific measures will be assessed

### **Completion date**

20/12/2021

## **Eligibility**

### **Key inclusion criteria**

Current participant inclusion criteria as of 08/03/2022:

1. Aged 25-45 years
2. Healthy
3. Office worker (work sitting at a desk indoors for the working day)
4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September/October/November/December 2021
5. Working within the Oxford Ring Road, full-time ("9-5", Monday-Friday), in August/September/October/November/December 2021
6. Android/iOS smartphone user (with a consistent internet connection indoors and outdoors)
7. Able to read and understand English

Previous participant inclusion criteria as of 07/10/2021:

1. Aged 25-45 years
2. Healthy
3. Office worker (work sitting at a desk indoors for the working day)
4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September/October/November 2021
5. Working within the Oxford Ring Road, full-time ("9-5", Monday-Friday), in August/September/October/November 2021
6. Smartphone user (with a consistent internet connection indoors and outdoors)
7. Able to read and understand English

Previous participant inclusion criteria:

1. Aged 25-45 years
2. Healthy
3. Office worker (work sitting at a desk indoors for working day)
4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September 2021
5. Working within the Oxford Ring Road, full-time ("9-5", Monday-Friday), in August/September 2021
6. Working from home, full-time ("9-5", Monday-Friday), in August/September 2021
7. Android smartphone user (with a consistent internet connection indoors and outdoors)
8. Able to read and understand English

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

Current participant exclusion criteria as of 08/03/2022:

1. Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, PTSD (GAD-7;  $\geq 10$ )
2. Major Depression (PHQ-9;  $\geq 10$ )
3. Suicidal ideation with intent or attempted suicide within past 2 months
4. Formal diagnosis of a mental health disorder
5. Extreme early and late chronotypes ( $\mu$ MCTQ;  $\leq 2$  or  $\geq 6$ )
6. Shift or night worker in the past 3 months
7. Formal diagnosis of a sleep disorder
8. Drug abuse (DAST-10;  $\geq 3$ )
9. Alcohol use disorder (AUDIT;  $\geq 16$ )
10. Caffeine dependence (SDS;  $\geq 4$ )
11. Sleep medication
12. Smoker/vape user
13. Antidepressants (e.g., serotonin reuptake inhibitors)
14. Anxiety medication
15. Photosensitive medication
16. Benzodiazepines or non-benzodiazepine hypnotics
17. Beta/alpha blockers
18. Underweight and obese BMI (less than 18.5 or greater than 29.9 kg/m<sup>2</sup>)
19. Significant medical or surgical condition
20. Planning major surgery in the next 6 months
21. Significant pain or physical distress
22. Serious head injury in the past year
23. Neurological disorder
24. Neurodevelopmental disorder
25. Physical disability preventing moderate exercise (e.g., going for a 30-min walk)
26. Eye disease

27. Life expectancy <1 year
28. Menopausal
29. Lactating or pregnant
30. Significant recent, or foreseeable life events (death in family, moving to a new house, divorce)
31. Undergone light therapy in the last month/plan to have light therapy within the next 6 months
32. Received/receiving psychological treatment for a sleep disorder
33. Currently taking part in a study involving a drug or behavioural intervention/ will be taking part in such a study in the next 3 months
34. Knowing of someone who is participating/has participated in the data collection aspect of this study

Previous participant exclusion criteria as of 07/10/2021:

1. Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, PTSD (GAD-7;  $\geq 10$ )
2. Major Depression (PHQ-9;  $\geq 10$ )
3. Suicidal ideation with intent or attempted suicide within past 2 months
4. Formal diagnosis of a mental health disorder
5. Extreme early and late chronotypes ( $\mu$ MCTQ;  $\leq 2$  or  $\geq 6$ )
6. Shift or night worker in the past 3 months
7. Formal diagnosis of a sleep disorder
8. Drug abuse (DAST-10;  $\geq 3$ )
9. Alcohol use disorder (AUDIT;  $\geq 16$ )
10. Caffeine dependence (SDS;  $\geq 4$ )
11. Sleep medication
12. Smoker/vape user
13. Antidepressants (e.g., serotonin reuptake inhibitors)
14. Anxiety medication
15. Photosensitive medication
16. Benzodiazepines or non-benzodiazepine hypnotics
17. Beta/alpha blockers
18. Underweight and obese BMI (less than 18.5 or greater than 29.9 kg/m<sup>2</sup>)
19. Significant medical or surgical condition
20. Planning major surgery in the next 6 months
21. Significant pain or physical distress
22. Serious head injury in the past year
23. Neurological disorder
24. Neurodevelopmental disorder
25. Physical disability preventing moderate exercise (e.g., going for a 30-min walk)
26. Eye disease
27. Life expectancy <1 year
28. Menopausal
29. Lactating or pregnant
30. Significant recent, or foreseeable life events (death in family, moving to a new house, divorce)
31. Undergone domain-specific therapy in the last month/plan to have domain-specific therapy within the next 6 months
32. Received/receiving psychological treatment for a sleep disorder
33. Currently taking part in a study involving a drug or behavioural intervention/ will be taking part in such a study in the next 3 months
34. Knowing of someone who is participating/has participated in the data collection aspect of this study

Previous participant exclusion criteria:

1. Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, PTSD (GAD-7;  $\geq 10$ )
2. Major Depression (PHQ-9;  $\geq 10$ )
3. Suicidal ideation with intent or attempted suicide within past 2 months
4. Formal diagnosis of a mental health disorder
5. Poor sleepers (PSQI;  $> 5$ )
6. Extreme early and late chronotypes ( $\mu$ MCTQ;  $\leq 2$  or  $\geq 6$ )
7. Shift or night worker in the past 3 months
8. Formal diagnosis of a sleep disorder
9. Drug abuse (DAST-10;  $\geq 3$ )
10. Alcohol use disorder (AUDIT;  $\geq 8$ )
11. Caffeine dependence (SDS;  $\geq 4$ )
12. Sleep medication
13. Smoker/vape user
14. Antidepressants (e.g., serotonin reuptake inhibitors)
15. Anxiety medication
16. Photosensitive medication
17. Benzodiazepines or non-benzodiazepine hypnotics
18. Beta/alpha blockers
19. Underweight and obese BMI (less than 18.5 or greater than 29.9 kg/m<sup>2</sup>)
20. Significant medical or surgical condition
21. Planning major surgery in the next 6 months
22. Significant pain or physical distress
23. Serious head injury in the past year
24. Neurological disorder
25. Neurodevelopmental disorder
26. Physical disability preventing moderate exercise (e.g., going for a 30-min walk)
27. Eye disease
28. Life expectancy  $< 1$  year
29. Menopausal
30. Lactating or pregnant
31. Significant recent, or foreseeable life events (death in family, moving to a new house, divorce)
32. Undergone domain-specific therapy in the last month/plan to have domain-specific therapy within the next 6 months
33. Tracking your health using a device/app (Fitbit, sleep application, diet tracker, etc)
34. Received/receiving psychological treatment
35. Received/receiving psychological treatment for a sleep disorder
36. Currently taking part in a study involving a drug or behavioural intervention/ will be taking part in such a study in the next 3 months
37. Knowing of someone who is participating/has participated in the data collection aspect of this study

**Date of first enrolment**

17/07/2021

**Date of final enrolment**

31/10/2021

**Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre****University of Oxford**

Department of Experimental Psychology

Anna Watts Building

Radcliffe Observatory Quarter

Woodstock Rd

Oxford

United Kingdom

OX2 6GG

**Sponsor information****Organisation**

University of Oxford

**ROR**

<https://ror.org/052gg0110>

**Funder(s)****Funder type**

Research organisation

**Funder Name**

Wellcome Trust

**Alternative Name(s)**

Wellcome, WT

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

**Funder Name**

SLL

**Funder Name**

St. Catherine's College, University of Oxford

**Alternative Name(s)**

St Catherine's College, University of Oxford, St Catherine's College Oxford

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

United Kingdom

**Funder Name**

Department of Experimental Psychology, University of Oxford

**Funder Name**

University of Oxford Medical Sciences Internal Fund

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored on the Open Science Framework.

**IPD sharing plan summary**

Stored in repository